Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for June 24, 2020

6/24/2020

 
Regulatory Update

The FDA approved lurbinectedin (Zepzelca, Jazz Pharma/PharmaMar) on 6/16/2020 for the treatment of metastatic small cell lung cancer that has progressed during or after treatment with platinum-based chemotherapy.
 
The FDA rejected Nabriva Therapeutics/Zavante Therapeutics’ injectable fosfomycin a second time in June 2020 due to the same manufacturing deficiencies found in 2019.
 
The FDA has accepted the NDA for Myovant’s relugolix for the treatment of advanced prostate cancer, and set a PDUFA date of 12/20/2020.
 
The FDA designated Insmed’s brensocatib as a Breakthrough Therapy for the treatment of non-cystic fibrosis bronchiectasis.
 
TG Therapeutics submitted an NDA for umbralisib for the treatment of marginal zone lymphoma and follicular lymphoma.
 
The FDA requested additional information on the efficacy analysis for Clovis Oncology’s rociletinib.
 
The FDA has granted Ovid Therapeutics’ gaboxadol a Rare Pediatric Disease designation for the treatment of Angelman syndrome.
 
The FDA has designated Chi-Med/Lilly’s fruquintinib Fast Track status for the treatment of patients with metastatic colorectal cancer.
 
Announced Research Updates

​Brickell announced that in a 42-day, 281 patient, Phase III trial, 53.9% of patients treated with sofpironium improved their Hyperhidrosis Disease Severity Scale to two or less and had a 50% or more reduction in gravimetric sweat production compared to 36.4% that received placebo in Japanese patients with axillary hyperhidrosis.
 
Global Data announced that a pooled analysis of six Phase II trials found that two months after midomafetamine treatment, 56% of patients did not meet PTSS diagnostic criteria and after 12 months, 67% did not qualify for a PTSD diagnosis.
 
BeyondSpring announced interim data from 120 patients enrolled in the Phase III PROTECTIVE 2 trial, where treatment with plinabulin plus pegfilgrastim reduced grade 4 or severe neutropenia, compared to pegfilgrastim monotherapy, in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
 
Hua Medicine announced that in a 24-week, 463 patient, Phase III SEED trial, treatment with dorzagliatin 0.75 mg reduced HbA1c 1.15% compared to a 0.58% decrease with placebo, in Chinese patients with type 2 diabetes. In a 28-week, open-label extension of the SEED trial, patients treated with dorzagliatin continued on the drug and maintained a 1.11% HbA1c reduction, while patients switched from placebo achieved a 1.27% reduction.
 
Roche announced that in the 1,101 patient, Phase II, IPATential150 trial, ipatasertib, added to abiraterone and prednisone or prednisolone, improved radiographic progression-free survival compared to abiraterone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss, but not in all mCRPC patients regardless of PTEN status.
 
Provention Bio announced extended follow-up data showing that the time to develop type 1 diabetes after treatment with teplizumab increased to five years compared to two years with placebo.
 
Sanofi announced that in a 2.4 year, 34-patient follow-up to a Phase II trial, treatment with fitusiran lowered the annualized bleed rates to 0.84 in the non-inhibitor subgroup and to 0.44 in the inhibitor subgroup.
 
Published Research Updates
 
In the 12-week, 155 patient, Phase IIb ASTEROID 2 trial, 62.9% of patients treated with vilaprisan had a complete absence of bleeding or spotting compared to 55.4% with ulipristal and none with placebo in patients with uterine fibroids and heavy menstrual bleeding.
 
In an 8-week, 9 patient, open-label pilot study, treatment with ganaxolone decreased the Montgomery-Asberg Depression Rating Scale [MADRS] score from 24.4 to 12.8, and 44% achieved remission (MADRS < 10) in postmenopausal women with persistent depression despite adequate antidepressant therapy.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.